GYKI-16638 is a novel antiarrhythmic agent that demonstrates combined class IB and class III antiarrhythmic properties in human ventricular muscles, similar to the electrophysiological findings after chronic amiodarone treatment. In addition, GYKI 16638 has an in vivo antiarrhythmic effect comparable to that of D-sotalol.